Glen Eagle Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

Glen Eagle Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6	Closed	-$53	–	941
2021 Q3	$53	Hold	6	–	–	﹤0.01%	1048
2021 Q2	$47	Hold	6	–	–	﹤0.01%	1033
2021 Q1	$46	Hold	6	–	–	﹤0.01%	997
2020 Q4	$47	Hold	6	–	–	﹤0.01%	967
2020 Q3	$58	Buy	+6	New	+$66	﹤0.01%	906

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glen Eagle Advisors's ATNM Position: Q4 2021 in Review

Glen Eagle Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q4 2021, closing a stake of 6 shares — an estimated $53 sold.

Glen Eagle Advisors first reported a position in ATNM in Q3 2020 and held it in 5 quarters. The position peaked at $58 in Q3 2020. 42 funds tracked by Wall St. Rank hold ATNM as of Q4 2021.

Glen Eagle Advisors reported no remaining Actinium Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Glen Eagle Advisors sold 6 Actinium Pharmaceuticals shares in Q4 2021, an estimated $53.
Glen Eagle Advisors first reported a position in Actinium Pharmaceuticals in Q3 2020 and held it in 5 quarters.
Glen Eagle Advisors's Actinium Pharmaceuticals position peaked at $58 in Q3 2020.
42 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.